UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2022

FORTE BIOSCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)

 
					
Delaware	 	001-38052	 	26-1243872	
(State or Other Jurisdiction
of Incorporation)	 	(Commission
File Number)	 	(IRS Employer
Identification No.)	

3060 Pegasus Park Dr.
Building 6
Dallas, Texas	 		 	75247	
(Address of Principal Executive Offices)	 		 	(Zip Code)	
Registrant’s Telephone Number, Including Area Code: (310) 618-6994
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	 	Trading
Symbol(s)	 	Name of each exchange
on which registered	
Common Stock, $0.001 par value	 	FBRX	 	The NASDAQ Stock Market LLC	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

Item 8.01.	Other Events.	
As previously reported, on March 31, 2022, the Company entered into an At Market Issuance Sales Agreement (the “Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”). Under the Agreement, the Company may offer and sell its common stock, par value $0.001 per share, from time to time having an aggregate offering price of up to $25,000,000 (the “Shares”) during the term of the Agreement through Ladenburg. The Company previously filed a prospectus supplement relating to the offer and sale of the Shares pursuant to the Agreement covering sales of up to $7,000,000 of Shares.
On August 12, 2022, the Company filed a new prospectus supplement (the “Prospectus Supplement”) relating to the offer and sale of the Shares pursuant to the Agreement covering sales of up to an additional $2,700,000 of Shares. The Shares will be issued pursuant to the Company’s previously filed and effective Registration Statement on Form S-3 (File No. 333-256611), which was initially filed with the Securities and Exchange Commission on May 28, 2021, and declared effective on June 7, 2021. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including funding existing and potential new clinical programs.
The opinion of the Company’s counsel regarding the validity of the Shares that may be issued pursuant to the Prospectus Supplement is filed herewith as Exhibit 5.1.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy Shares, nor shall there be any sale of the Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
 
Item 9.01.	Financial Statements and Exhibits.	
(d)    Exhibits

Exhibit	  		Description	
			
5.1	  	Opinion Of Wilson Sonsini Goodrich & Rosati, PC.		
			
104	  	The cover page of this Current Report on Form 8-K, formatted in inline XBRL		

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	 		 	FORTE BIOSCIENCES, INC.	
				
Date: August 12, 2022	 		 	By:	 	/s/ Antony Riley	
	 		 		 	Antony Riley	
	 		 		 	Chief Financial Officer	

Exhibit 5.1
August 12, 2022
Forte Biosciences, Inc.
3060 Pegasus Park Drive
Building 6
Dallas, TX 75247
 
Re:	Registration Statement on Form S-3	
Ladies and Gentlemen:
We have acted as counsel to Forte Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the registration of the offer and sale of up to $2,700,000 of shares (the “Shares”) of the Company’s common stock, $0.001 par value per share, pursuant to the Company’s shelf Registration Statement on Form S-3 (File No. 333-256611), filed on May 28, 2021 and declared effective by the Securities and Exchange Commission (the “Commission”) on June 7, 2021 (the “Registration Statement”).
The offering and sale of the Shares are being made pursuant to the At Market Issuance Sales Agreement (the “Sales Agreement”) dated as of March 31, 2022 by and between the Company and Ladenburg Thalmann & Co. Inc.
We have examined copies of the Sales Agreement, the Registration Statement, the base prospectus that forms a part thereof and the prospectus supplement thereto related to the offering of the Shares, which prospectus supplement is dated as of the date hereof and will be filed by the Company in accordance with Rule 424(b) promulgated under the Securities Act of 1933. We have also examined instruments, documents and records which we deemed relevant and necessary for the basis of our opinion hereinafter expressed.
In such examination, we have assumed (i) the authenticity of original documents and the genuineness of all signatures, (ii) the conformity to the originals of all documents submitted to us as copies, and (iii) the truth, accuracy, and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates we have reviewed.
Based on and subject to the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance with the terms of the Sales Agreement, will be validly issued, fully paid and nonassessable.
We express no opinion as to the laws of any other jurisdiction other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.
We hereby consent to the use of this opinion as an exhibit to the Company’s Current Report on Form 8-K filed on or about August 12, 2022 for incorporation by reference into the Registration Statement.

Sincerely,	
	
/s/ WILSON SONSINI GOODRICH & ROSATI	
	
WILSON SONSINI GOODRICH & ROSATI	
Professional Corporation